Citation for final published version:


Publishers page: http://dx.doi.org/10.1016/S2215-0366(21)00046-8

Please note:
Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher’s version if you wish to cite this paper.

This version is being made available in accordance with publisher policies. See http://orca.cf.ac.uk/policies.html for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.
Title: Severe mental illness and European COVID-19 vaccination strategies

Livia J. De Picker MD PhD<sup>a,b</sup>, Marisa Casanova Dias MRCPsych MSc<sup>c,d</sup>, Michael E. Benros MD PhD<sup>e</sup>, Benedetta Vai PhD<sup>f,h</sup>, igor Branchi PhD<sup>i</sup>, Francesco Benedetti MD PhD<sup>j,k</sup>, Alessandra Borsini PhD<sup>k</sup>, Juan Carlos Leza MD PhD<sup>I</sup>, Hilka Kärkkäinen BSocSc<sup>m</sup>, Miia Männikkö MSocSc<sup>n</sup>, Carmine M. Pariante MD PhD<sup>k</sup>, Ekin Sönmez Güngör MD<sup>p</sup>, Anna Szczegielniak MD<sup>q</sup>, Ryad Tamouza MD PhD<sup>r,s</sup>, Afra van der Markt MD<sup>t</sup>, Paolo Fusar-Poli MD PhD<sup>u,v</sup>, Julian Beezhold MBChB FRCPsych<sup>w,x</sup>, Marion Leboyer MD PhD<sup>y,z</sup>

Affiliations:

a. University Psychiatric Hospital Campus Duffel, Duffel, Belgium. Email: livia.depicker@emmaus.be
b. Collaborative Antwerp Psychiatric Research Institute, University of Antwerp, Antwerp, Belgium. Email: livia.depicker@uantwerp.be
c. National Centre for Mental Health, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University. Email: casanovadiasm@cardiff.ac.uk
d. Section of Women's Mental Health, Institute of Psychiatry, Psychology and Neurosciences, King's College London
e. Copenhagen Research Centre for Mental Health, Copenhagen University Hospital, Denmark. Email: Michael.Eriksen.Benros@regionh.dk
f. Department of Immunology & Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark
g. Psychiatry & Clinical Psychology, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milano, Italy. Email: vai.benedetta@hsr.it; benedetti.francesco@hsr.it
h. Fondazione Centro San Raffaele, Italy
i. Center for Behavioral Sciences and Mental Health, Istituto Superiore di Sanità, Rome, Italy. Email: igor.branchi@iss.it
j. University Vita-Salute San Raffaele, Milano, Italy
k. Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, United Kingdom. Email: alessandra.borsini@kcl.ac.uk; carmine.pariante@kcl.ac.uk
l. Department of Pharmacology & Toxicology, Faculty of Medicine, Universidad Complutense Madrid, CIBERSAM, Imas12, IUNQ. Madrid, Spain. Email: jcleza@med.ucm.es
m. Global Alliance of Mental Illness Advocacy Networks-Europe. Email: hilkkakarkkainen@gmail.com
n. European Federation of Associations of Families of People with Mental Illness. Email: miia.mannikko@hotmail.com
o. University of Health Sciences, Erenköy Mental Health and Neurological Diseases Training and Research Hospital, Istanbul, Turkey. Email: ekinsommez88@gmail.com
p. Department of Psychiatric Rehabilitation, Faculty of Medical Sciences in Katowice, Medical University of Silesia in Katowice, Poland. Email: anna.szczegielniak@gmail.com
q. Université Paris Est Creteil (UPEC), Inserm U 955, IMRB Translational Neuropsychiatry Lab, F-94010 Creteil, France. Email: tamouza.ryad@gmail.com; marion.leboyer@inserm.fr
r. AP-HP, Hôpitaux Universitaires H. Mondor, DMU IMPACT, FHU ADAPT, F-94010, Créteil, France
s. Fondation FondaMental, Créteil, France
t. Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Public Health Research Institute, The Netherlands. Email: a.vandermarkt@ggzingeest.nl
u. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, United Kingdom. Email: paolo.fusar-poli@kcl.ac.uk
v. Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
w. Norwich Medical School, University of East Anglia, United Kingdom. Email: j.beezhold@uea.ac.uk
x. Mental Health Liaison Service, Norwich and Norfolk University Hospital, Norfolk and Suffolk NHS Foundation Trust, Norwich, United Kingdom

*Corresponding author: livia.depicker@uantwerp.be; +32 15 30 38 47

Postal address: Wetenschappelijk Onderzoek t.a.v. Livia De Picker
UPC Duffel
Stationstraat 22c
2570 Duffel
Belgium

Keywords: COVID-19; SARS-CoV-2; vaccine; vaccination; severe mental illness; schizophrenia; mental health policy; psychiatry; Europe
The European Union advises prioritising for vaccination “persons whose state of health makes them particularly at risk” for severe COVID-19, but leaves it to member states to decide which medical conditions to prioritise. Ethical, neuroscientific, and public health considerations have been emphasized to prioritise individuals with severe mental illness (i.e., psychotic disorders, bipolar disorders, and severe major depressive disorders).

We systematically reviewed national COVID-19 vaccine deployment plans across 20 European countries (cfr. Appendix).

Eight of 20 countries’ national vaccine strategy documents explicitly mentioned psychiatry or mental illness. Several countries prioritised institutional residents, which may include severe mental illness (Table 1). Only four countries (Denmark, Germany, the Netherlands, and the UK) had some form of higher vaccination priority for outpatients with severe mental illness. Additionally, Latvia, Romania, Spain, and Sweden prioritised outpatients with disabilities, possibly including severe mental illness, whereas the Czech Republic and Sweden stipulated behavioural or mental problems possibly hindering pandemic regulation adherence as priority indication.

A European Centre for Disease Control and Prevention survey found most European countries used a combination of epidemiological data, mathematical modelling, guidelines, ethical considerations, and published research findings to define specific morbidities for vaccine prioritisation.

Examples of approaches with positive outcomes for severe mental illness include:

The UK used an Oxford University evidence-based algorithm to calculate the number of vaccinations needed to prevent one death. Importantly, this QCovid® algorithm (https://qcovid.org/; Copyright © 2020, University of Oxford), based on April-June 2020 UK data, explicitly includes severe mental illness among its risk predictors, and so does the UK vaccination strategy. Preliminary data however indicate vaccination coverage for patients with severe mental illness is lagging behind that of other co-morbidity groups.

Denmark and the Netherlands initially omitted mental disorders from their COVID-19 vaccination strategies. After a large nationwide cohort study found that severe mental illness and use of antipsychotics were associated with an increased risk for 30-day mortality (adjusted OR 2.5; 95%CI 1.2-5.1 and 3.3; 95%CI 2.3-4.8, respectively), the Danish Health Authority urged healthcare practitioners to refer for priority vaccination patients with psychotic disorders and other individuals with complex severe mental illness deemed to be at particular high risk by the treating physician. The Netherlands increased prioritisation of severe mental illness patients following advocacy from mental health associations.

The German federal research institute performed an “umbrella review” of published systematic reviews and meta-analyses to inform the federal ministry of health’s selection of risk comorbidities. However, evidence on psychiatric morbidity had not yet been systematically summarized at that time and was therefore not included in the resulting strategy. Following a recent update of its literature review, in which severe mental illness was found to be one of the few medical comorbidities with OR >2.0 for COVID-19 hospitalisation and mortality, the strategy now explicitly includes severe mental illness in the highest risk group of medical comorbidities.

Multiple high-quality studies have demonstrated odds ratios for comorbid severe mental illness, and schizophrenia in particular, to equal or even surpass those of other risk comorbidities included for prioritisation (Table 1). Evidence-based policy would then require severe mental illness be included in the list of risk comorbidities. Yet several sources of bias may have caused the risks associated with severe mental illness to be overlooked by most countries. Firstly, mental disorders are often not included as predictors in COVID-19 outcome studies. Secondly, studies specifically investigating the risks of psychiatric comorbidity were not yet summarized in systematic reviews or meta-analyses and therefore ignored by some national strategies and mathematical models.

In summary, there is a compelling medical, ethical, and economic case for targeted early vaccination for the vulnerable group of patients with severe mental illness. Our joint recommendations, representing professionals, patients, and families, are clear and urgent: (1) explicit inclusion of both inpatients and outpatients with severe mental illness in medical priority groups for COVID-19 vaccination, (2) meaningful patient- and family organisational participation in developing vaccination plans, and (3) engagement of peer workers in providing vaccination education to patients.

European countries’ vaccination strategies try to balance ethical and scientific evidence, but for individuals with severe mental illness an evidence-policy disconnect remains. Most of these patients are treated in the community,
yet these individuals are overlooked by the majority of European COVID-19 vaccination strategies. Information collected in this report is not definitive or exhaustive. Countries are still developing vaccination plans and strategies may change as knowledge evolves. EU member states have been asked to share best practices for prioritisation through the Health Security Committee, coordinated by the European Commission.

We therefore call on the European authorities (Council, Parliament and Commission), as well as national health authorities and the scientific community to take note of the summarized evidence and recommendations outlined in this paper, and to correct this intolerable inequality.

References

Acknowledgements
This paper has been developed collaboratively and has received endorsements from the most prominent European psychiatric associations: (in alphabetical order) the European College of Neuropsychopharmacology (ECNP), the European Psychiatric Association (EPA), the European Federation of Associations of Families of People with Mental Illness (EUFAMI), the Global Alliance of Mental Illness Advocacy Networks-Europe (GAMIAN-Europe) and the European Union of Medical Specialists Section of Psychiatry (UEMS-Psychiatry).

The authors would like to express their utmost gratitude to our network of local representatives who helped to identify, collect and review the national strategy documents, and provided additional information derived from their personal clinical experience and the national psychiatric associations: Pavel Trancik (Czech Republic Paula Mustonen (Finland), Jördis Rausch (Germany), Thanos Khanellopoulos (Greece), Zetti Azvee (Ireland), Liene Berze (Latvia), Giovanni Grech (Malta), Morten Svendal Hatlen (Norway), Miguel Bajuoco (Portugal), Celso Arango and Eduard Vieta (Spain), Stanko Medic, Amelie Kjellstenius and Tove Mogren (Sweden).
Funding and conflict of interest

No specific funding was received for the current work. Several authors are involved in international psychiatric associations (see Appendix). Other than this, the authors report no conflict of interest related to the current work. Dr. De Picker reports research grants from Boehringer-Ingelheim and Janssen R&D, outside the submitted work. Dr. Fusar Poli reports personal fees from Menarini, personal fees from Angelini, personal fees from Lundbeck, outside the submitted work. Professor Leboyer reports personal fees from Janssen, personal fees from Sanofi, educational grants from Otsuka and Lundbeck, and research grants from Roche, all outside the submitted work. Professor Pariante has received research and consultancy funding from Johnson & Johnson and Boehringer Ingelheim; moreover, Professor Pariante is funded by a Wellcome Trust strategy award to the Neuroimmunology of Mood Disorders and Alzheimer’s Disease (NIMA) Consortium (104025), which is also funded by Janssen, GlaxoSmithKline, Lundbeck and Pfizer; all outside the submitted work. Professor Pariante is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King’s College London, and by a NIHR Senior Investigator. Co-authors MEB, BV, IB, FB, AS, HK, MM, ESG, JCL, AVDM, AB, RT and JB have nothing to disclose.

Author contributions

LDP, CP and ML conceptualized the study. LDP, ES, AS, JB and MCD collected and reviewed the data on country national vaccination strategies. IB, FB, BV, PFP, MEB and RT performed a literature search of the effect of psychiatric comorbidities on COVID-19 outcomes. JB, HK and MM created the best-practice recommendations. All authors provided feedback and helped revise the manuscript.